SUPN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SUPN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). Supernus Pharmaceuticals's Average Total Inventories for the three months ended in Dec. 2024 was $59.1 Mil. Supernus Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2024 was $26.1 Mil. Hence, Supernus Pharmaceuticals's Days Inventory for the three months ended in Dec. 2024 was 206.77.
The historical rank and industry rank for Supernus Pharmaceuticals's Days Inventory or its related term are showing as below:
During the past 13 years, Supernus Pharmaceuticals's highest Days Inventory was 572.77. The lowest was 260.75. And the median was 384.25.
Supernus Pharmaceuticals's Days Inventory declined from Dec. 2023 (374.00) to Dec. 2024 (206.77).
Inventory Turnover measures how fast the company turns over its inventory within a year. Supernus Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2024 was 0.44.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Supernus Pharmaceuticals's Inventory-to-Revenue for the three months ended in Dec. 2024 was 0.34.
The historical data trend for Supernus Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
260.75 | 326.49 | 371.40 | 368.03 | 308.52 |
Supernus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
Days Inventory | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
374.00 | 426.59 | 364.76 | 342.87 | 206.77 |
For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Supernus Pharmaceuticals's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Supernus Pharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2024 is calculated as
Days Inventory (A: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2023 ) | + | Total Inventories (A: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2024 ) | * | Days in Period |
= | ( (77.408 | + | 54.293) | / | 2 ) | / | 77.906 | * | 365 |
= | 65.8505 | / | 77.906 | * | 365 | ||||
= | 308.52 |
Supernus Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2024 is calculated as:
Days Inventory (Q: Dec. 2024 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2024 ) | + | Total Inventories (Q: Dec. 2024 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2024 ) | * | Days in Period |
= | ( (63.981 | + | 54.293) | / | 2 ) | / | 26.098 | * | 365 / 4 |
= | 59.137 | / | 26.098 | * | 365 / 4 | ||||
= | 206.77 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Supernus Pharmaceuticals (NAS:SUPN) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Supernus Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2024 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 26.098 | / | 59.137 | |
= | 0.44 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Supernus Pharmaceuticals's Inventory to Revenue for the three months ended in Dec. 2024 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 59.137 | / | 174.159 | |
= | 0.34 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan Rubin | officer: SVP, Chief Medical Officer | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Padmanabh P. Bhatt | officer: Sr. VP of IP, CSO | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Newhall Charles W Iii | director | 1119 ST PAUL ST, BALTIMORE MD 21202 |
Frederick M. Hudson | director | 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Jack A. Khattar | director, officer: President, CEO | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Georges Gemayel | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Frank Mottola | officer: Sr VP, Quality, GMP Oper. & IT | 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Tami Tillotson Martin | officer: Sr. V.P., Regulatory Affairs | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Bethany Sensenig | director | C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
Timothy C Dec | officer: Senior Vice-President & CFO | C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878 |
Schwabe Stefan K.f. | officer: Executive Vice President R&D | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Gregory S Patrick | officer: VP, Chief Financial Officer | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
James Patrick Kelly | officer: Executive Vice-President & CFO | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Carrolee Barlow | director | C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850 |
Victor Vaughn | officer: Sr. VP of Sales | C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850 |
From GuruFocus
By GuruFocus News • 02-03-2025
By GuruFocus News • 03-04-2025
By GuruFocus News • 02-19-2025
By GlobeNewswire • 11-26-2024
By GuruFocus News • 02-25-2025
By Marketwired • 11-13-2024
By Marketwired • 02-04-2025
By GuruFocus News • 11-05-2024
By Marketwired • 02-25-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.